ISSN 1016-5169 | E-ISSN 1308-4488
Archives of the Turkish Society of Cardiology
pdf
The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2015; 43(2): 1-6

The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses

Adnan Abacı
Gazi University Faculty of Medicine, Department of Cardiology, Ankara, Turkey

Prasugrel, a third generation P2Y12 receptor inhibitor, is more powerful than clopidogrel. TRITON-TIMI 38 trial compared the effectiveness of prasugrel with clopidogrel in patients with STEMI and NSTEMI. This paper examined the main TRITON-TIMI 38 trial and subgroup analyses of the trial to determine patient subgroups in which prasugrel is superior to clopidogrel in preventing clinical events without an additional increase in bleeding risk. In such patients, one might expect to derive optimal benefit from prasugrel without a significant increase in bleeding.

Keywords: prasugrel, STEMI, NSTEMI, clopidogrel

How to cite this article
Adnan Abacı. The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses. Turk Kardiyol Dern Ars. 2015; 43(2): 1-6

Corresponding Author: Adnan Abacı, Türkiye
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.